Abstracts tagged "Malignancy"

Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
Abstract Number: 1523 • ACR Convergence 2021
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
Megan Hansen, Danny Zakria and Douglas Johnson, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…
Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Suguru Honda¹, Ryoko Sakai ², Masako Majima ¹, Naoko Konda ¹, Hideto Takada ¹, Kazuhiko Yamamoto ³, Tsutomu Takeuchi ⁴ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Sasha Bernatsky¹, Rosalind Ramsey-Goldman ², Murray Urowitz ³, John Hanly ⁴, Caroline Gordon ⁵, Michelle Petri ⁶, Ellen M Ginzler ⁷, Daniel J Wallace ⁸, Sang-Cheol Bae ⁹, Juanita Romero-Diaz ¹⁰, MA Dooley ¹¹, Christine Peschken ¹², David A Isenberg ¹³, Anisur Rahman ¹⁴, Susan Manzi ¹⁵, Soren Jacobsen ¹⁶, S Sam Lim ¹⁷, Ronald F Van Vollenhoven ¹⁸, Ola Nived ¹⁹, Diane Kamen ²⁰, Cynthia Aranow ²¹, Jill Buyon ²², Guillermo Ruiz-Irastorza ²³, Ian Bruce ²⁴, Dafna Gladman ²⁵, Paul Fortin ²⁶, Joan T. Merrill ²⁷, Jorge Sanchez-Guerrero ²⁸, Kenneth C Kalunian ²⁹, Kristjan Steinsson ³⁰, Manuel Ramos ³¹, Asad Zoma ³², Thomas Stoll ³³, Munther A Khamashta ³⁴, Murat Inanc ³⁵ and Ann E Clarke ³⁶, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷State University of New York Downstate Medical Center, Brooklyn, NY, ⁸Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ¹¹UnC Kidney Centre, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, Canada, ¹³Centre for Rheumatology, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Allegheny Health Network, Pittsburg, PA, ¹⁶Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²NYU School of Medicine, New York, ²³Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ²⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ²⁷Okalahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Toronto Western Hospital, Toronto, ON, Canada, ²⁹UC San Diego School of Medicine, LaJolla, CA, ³⁰Landspitali, University Hospital, Reykjavik, Iceland, ³¹Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³²Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ³³University of Glasgow, Kilbride, Scotland, United Kingdom, ³⁴King's College London School of Medicine, London, United Kingdom, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶University of Calgary, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 365 • 2018 ACR/ARHP Annual Meeting
Monoclonal Gammopathy in Rheumatic Diseases
Yue Yang, Yuan Jia, Shi Chen, Yin Su and Zhan-Guo Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To analyze the clinical spectrum, laboratory characteristics, and outcomes of monoclonal gammopathy (MG) in patients with rheumatic diseases. Methods: Screening for the presence of…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 1515 • 2018 ACR/ARHP Annual Meeting
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Naoto Tamura¹, Masataka Kuwana², Tatsuya Atsumi³, Syuji Takei⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Hiroaki Matsuno⁷, Tsuneyo Mimori⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Yoshinari Takasaki¹¹, Kazuto Nomura¹², Yutaka Endo¹², Tomohiro Hirose¹², Yosuke Morishima¹², Naonobu Sugiyama¹², Noritoshi Yoshii¹² and Michiaki Takagi¹³, ¹Juntendo University, Tokyo, Japan, ²Nippon Medical School, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Medical Center for Children, Kagoshima, Japan, ⁵Tokyo Women’s Medical University, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁸Kyoto University, Kyoto, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰The University of Tokyo, Tokyo, Japan, ¹¹Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, ¹²Pfizer Japan Inc, Tokyo, Japan, ¹³Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib have been demonstrated in patients (pts)…
Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Jean Tayar², Natalia Zamora³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Julia Tan¹, J. Antonio Avina-Zubieta², Alyssa Dominique³, Hamid Tavakoli⁴ and Teresa A Simon³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
Abstract Number: 273 • 2017 ACR/ARHP Annual Meeting
The Risk Factors of Developing Adult T Cell Leukemia (ATL) in Human T Cell Leukemia Virus Type 1 (HTLV-1) Positive Patients with Rheumatoid Arthritis in Endemic Area, Japan; A Retrospective Cohort Study
Kunihiko Umekita¹, Yayoi Hashiba², Shunichi Miyauchi¹, Kazuyoshi Kubo², Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Institute of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan
Background/Purpose: Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). ATL is an aggressive T-cell malignancy caused…
Abstract Number: 2739 • 2017 ACR/ARHP Annual Meeting
Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon⁹, Loïc Guillevin for the French Vasculitis Study Group³ and Benjamin Terrier¹⁰, ¹Medecine Interne, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁶nephrology, HEGP, Paris, France, ⁷Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Université Paris Descartes Sorbonne Paris, Paris, France, ¹⁰Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: The use of long-term immunosuppressive agents in patients with systemic necrotizing vasculitides has dramatically improved the overall prognosis, but expose patients to potential severe…
Abstract Number: 1193 • 2016 ACR/ARHP Annual Meeting
Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis
Khushboo Sheth^1,2, Chia-Ling Kuo³, Dhruv Modi⁴ and Christopher Scola⁵, ¹Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT, ⁴Internal Medicine, Jamaica Hospital and Medical Center, New York, NY, ⁵Rheumatology, Hartford Hospital, Hartford, CT
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients.…
Abstract Number: 1546 • 2016 ACR/ARHP Annual Meeting
Clinical Features at the Onset of Lymphoproliferative Disorder in Patients with Rheumatoid Arthritis
Daisuke Kobayashi^1,2, Satoshi Ito¹, Chinatsu Takai^1,3, Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³Department of clinical rheumatology and nephrology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: Rheumatoid arthritis (RA) is intrinsically associated with an increased incidence of lymphoproliferative disorders (LPDs). Although treatment with immunosuppressive agents, such as methotrexate, tacrolimus, or…
Abstract Number: 1685 • 2016 ACR/ARHP Annual Meeting
Updated Results for All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J Mease¹, Alice Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, Soumya Chakravarty⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷, Kavitha Goyal⁷ and Jose U. Scher^9,10, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: To describe characteristics & potential risk factors(including treatment exposure) for all-cause mortality & malignancies (excluding NMSC) in psoriasis (PsO) patients (pts) with psoriatic arthritis…
Abstract Number: 2605 • 2016 ACR/ARHP Annual Meeting
Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry
Dimitrios A. Pappas^1,2, Sabrina Rebello², Mei Liu², Jennifer Schenfeld³, YouFu Li⁴, David H. Collier³ and Neil Accortt³, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Recently issued guidelines suggest that rheumatoid arthritis (RA) patients with previously treated solid malignancy may be treated as patients without such history (1). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].